Faster Insulin: Does Speed Really Improve Blood Sugar Control?

What Was Studied and Why It Matters

Researchers in England wanted to know whether a newer, faster-acting mealtime insulin — called faster aspart (brand name Fiasp) — actually works better than standard rapid-acting insulins in real-world patients. This wasn't a controlled lab trial; it used real prescription records from over 11,000 people with type 1 or type 2 diabetes across England between 2017 and 2021. For people who struggle to match their insulin timing perfectly to meals, a faster-acting option could make a meaningful difference in daily life.

What the Researchers Did

The study looked at two groups: patients who were starting mealtime insulin for the first time, and patients who switched from a standard rapid-acting insulin to either faster aspart or another rapid-acting insulin. Researchers then tracked three important outcomes over the following months:

• Changes in HbA1c (a 3-month average blood sugar measure) at 6 months
• Hypoglycaemia (low blood sugar) episodes over 12 months
• How long patients stayed on their prescribed insulin without stopping

What They Found

The results were encouraging, particularly for people with type 1 diabetes:

• Better blood sugar control: In three out of four patient groups studied, faster aspart produced larger reductions in HbA1c compared to standard rapid-acting insulins.
• Fewer dangerous lows: People with type 1 diabetes who switched to faster aspart experienced a statistically significant reduction in hypoglycaemia episodes — a clinically important finding, since severe lows can be life-threatening.
• Patients stuck with it longer: Type 1 diabetes patients who switched to faster aspart were more likely to continue using it compared to those who switched to a standard rapid-acting insulin, suggesting they found it more effective or easier to use.

For type 2 diabetes patients, the differences were smaller and less consistent, though faster aspart still showed numerically better HbA1c reductions in most groups.

What This Means for Real Patients

If you manage type 1 diabetes and find that your blood sugar spikes after meals despite careful dosing, or if you frequently experience low blood sugar episodes, it may be worth discussing faster aspart with your diabetes care team. The fact that patients stayed on this insulin longer suggests real-world satisfaction — not just numbers on a chart.

Managing mealtime insulin effectively also depends on having reliable supplies on hand. Whether you use an insulin pen or syringe, MDS Diabetes carries the delivery supplies you need to stay consistent with your regimen without disruption.

For type 2 diabetes, the benefits were less dramatic, but your doctor can help you weigh whether a switch makes sense for your individual situation.

Bottom Line

A large real-world UK study found that faster aspart insulin lowered HbA1c more than standard rapid-acting insulins in most patient groups, and significantly cut hypoglycaemia rates in type 1 diabetes. Patients also tended to stay on it longer. If mealtime blood sugar control is a challenge for you, this research gives good reason to have a conversation with your healthcare provider about whether faster insulin could help.